- DocumentoOMCIJ.MS.ID.555853enviado por
Drkrishnasarma pathy
- DocumentoPatent Evaluation on Monoclonal Antibody (MAB) Therapy with Binding Specificity to CD20 B-Cell Surface Antigen Bp35 and the Manufacturing Process of Biological &Antibodies and Derivativesenviado por
Drkrishnasarma pathy
- DocumentoInternational Journal of Research Studies in Medical and Health Sciences-Antiviral nucleosides- Flu Viruses- QUINOLINES-COVID-19 Dr Krishna sarma pathyenviado por
Drkrishnasarma pathy
- DocumentoHCV NS3/4A 3 Protease Inhibitorsenviado por
Drkrishnasarma pathy
- DocumentoBJSTR.MS.ID.003667 Chronic Hepatitis (Chc), Viral Polymerase Nucleotide Inhibitor & Process Patents Review and Evaluation, Preparation of Sofosbuvirenviado por
Drkrishnasarma pathy
- DocumentoLOJMS.MS.ID.000121 An anti-inflammatory adrenocorticalsteroid Hydrocortisonesodiumsuccinate, hydrocortisone preparation and validated for the confirmation/ determination and quantification of hydrocortisoneenviado por
Drkrishnasarma pathy
- DocumentoAn Anti-Inflammatory Adrenocorticalsteroid Hydrocortisonesodiumsuccinate, Hydrocortisone Preparation and Validated for the Confirmation Determination and Quantification of Hydrocortisoneenviado por
Drkrishnasarma pathy
- Documentolojenviado por
Drkrishnasarma pathy
- Documentoconsiderationsenviado por
Drkrishnasarma pathy
- Documentocefpodoximeenviado por
Drkrishnasarma pathy
- Documentolojenviado por
Drkrishnasarma pathy
- Documentobjstr.ms.id.001662considerationsenviado por
Drkrishnasarma pathy
- Documentoconsiderationsenviado por
Drkrishnasarma pathy
- Documentobjstr.ms.id.001662considerationsenviado por
Drkrishnasarma pathy
- DocumentoJOJS.MS.ID.555566 (1)Case History-The Control of Impurities-A Critical Issue to The Active Pharmaceutical Ingredientenviado por
Drkrishnasarma pathy
- DocumentoCase History-The Control of Impurities-A Critical Issue to The Active Pharmaceutical Ingredient JOJ Scin 1(4) JOJS.ms.ID.555566 (2018) Krishnasarmapathyenviado por
Drkrishnasarma pathy
- DocumentoKrishnasarma Pathy K (2018) Entecavir Patent Evaluation & Genotoxicityenviado por
Drkrishnasarma pathy
- DocumentoHerald Scholarly Open AccessPathy K (2018) Entecavir Patent Evaluation & Genotoxicity. J Toxicol Cur Res 2 005.enviado por
Drkrishnasarma pathy
- DocumentoKrishnasarma Pathy K (2018) Entecavir Patent Evaluation & Genotoxicityenviado por
Drkrishnasarma pathy
- DocumentoJPP-18-RA-1899-Entecavir-patent-evaluation--method--for-diastereomeric-Impurities--/1899enviado por
Drkrishnasarma pathy
- DocumentoHttpswww.ommegaonline.orgarticle Details Entecavir Patent Evaluation Method for Diastereomeric Impurities 1899enviado por
Drkrishnasarma pathy
- DocumentoEntecavir Patent Evaluation, Method for Diastereomeric Impurities OMCIJ.MS.ID.555711enviado por
Drkrishnasarma pathy
- DocumentoPreparation of Vitamin C and Method for Determination of Vitamin C in Tablets SCSOAJ.ms.ID.000114enviado por
Drkrishnasarma pathy
- DocumentoRoute Evaluation and Analytical HPLC Method Development of Buprenorphine, Naloxone, And Comparison OverallSJFN.ms.ID.000105enviado por
Drkrishnasarma pathy
- DocumentoOMCIJ.MS.ID.555674 .enviado por
Drkrishnasarma pathy
- DocumentoSRMRCR-01-00014 (1)enviado por
Drkrishnasarma pathy
- DocumentoOAJT.ms.ID.555593 Krishnasarmapathyenviado por
Drkrishnasarma pathy
- DocumentoOAJT.ms.ID.555592krishnasarmapathyenviado por
Drkrishnasarma pathy
- DocumentoInt J clinical & case. 1:7, 140-144-The influenza A virus subtypes H1N1, H1N2 and H3N2 ,HDFxenviado por
Drkrishnasarma pathy
- DocumentoThe influenza A virus subtypes H1N1, H1N2 and H3N2 ,HDFxenviado por
Drkrishnasarma pathy
- DocumentoOAJT.MS.ID.555568 (1)Research Article Volume 1 Issue 4 - August 2017 DOIenviado por
Drkrishnasarma pathy
- DocumentoOAJT.MS.ID.555568 (1)enviado por
Drkrishnasarma pathy
- DocumentoMethod Development and Pharmacological study of Chemotherapeutic Agents OAJT.ms.ID.555568 Drkrishnasarmapathyenviado por
Drkrishnasarma pathy
- DocumentoBASIC SKILLS TRAINING GUIDE -HPLC method development and validation- an overview Dr Sarma Krishna pathy ,YLN Murthy,Sunithasarma,Atchuutha ramaiahenviado por
Drkrishnasarma pathy
- DocumentoBASIC SKILLS TRAINING GUIDE -HPLC Method Development and Validation- An Overview-1enviado por
Drkrishnasarma pathy
- DocumentoS- Amlo Besylateenviado por
Drkrishnasarma pathy
- DocumentoIndustrial process for OXICONAZOLE Dr krishnasarma Pathy step-I 2,2’4’-tri-choloroacetophenone,Imidazole reacted in presence of acetonitrile to form 1-(2,4-dichlorophenacyl)-imidazole (I).Which is then reacted with hydroxylamine. hydrochloride to give (Z)-1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl) ethanone oxime (II). It is further reacted with 2,4-Dichlorobenzyl chloride in presence of sodium hydride to give (III) Oxiconazole and finally salt formation with nitric acidenviado por
Drkrishnasarma pathy
- DocumentoArticleenviado por
Drkrishnasarma pathy
- DocumentoLab Notebook Example-Tris[(2-pyridyl)methyl]amineenviado por
Drkrishnasarma pathy
- DocumentoIPR - A Primer on Intellectual Property Rights-Dr KrishnasarmaPathyenviado por
Drkrishnasarma pathy
- DocumentoSolid-state Forms of Celecoxib and an Improved Process for the Preparation of Celecoxib Polymorphenviado por
Drkrishnasarma pathy
- DocumentoCELECOXIBenviado por
Drkrishnasarma pathy
- DocumentoIndustrial process for preparation of Levetiracetam.enviado por
Drkrishnasarma pathy
- DocumentoLevi Trace Tamenviado por
Drkrishnasarma pathy
- DocumentoIndustrial process for preparation of Levetiracetam.enviado por
Drkrishnasarma pathy
- DocumentoLevi Trace Tamenviado por
Drkrishnasarma pathy
- DocumentoVITAMIN Cenviado por
Drkrishnasarma pathy
- DocumentoPHENYLEPHRINEenviado por
Drkrishnasarma pathy
- DocumentoDEFINITION “IMPURITY”enviado por
Drkrishnasarma pathy